GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » 5-Year Yield-on-Cost %

Gene Biotherapeutics (Gene Biotherapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics 5-Year Yield-on-Cost %?

Gene Biotherapeutics's yield on cost for the quarter that ended in Dec. 2020 was 0.00.


The historical rank and industry rank for Gene Biotherapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



CRXM's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.895
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Gene Biotherapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Gene Biotherapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gene Biotherapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's 5-Year Yield-on-Cost % falls into.



Gene Biotherapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Gene Biotherapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Gene Biotherapeutics  (OTCPK:CRXM) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Gene Biotherapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines